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Introduction
The endometrium of primates, including humans, is 
a complex heterogeneous structure comprising two
major compartments, the glandular cells and the stromal
cells, which respond differently to the same hormonal
milieu [1]. Human endometrium undergoes significant
changes during the menstrual cycle, from the early pro-
liferative phase, through the late proliferative phase,
ovulatory phase, early secretory phase, midsecretory
phase and late secretory phase, to menstruation. The
regulatory mechanisms involve hormonal, immuno-
logic and genetic factors [2–6]. Differential display of
eukaryotic messenger RNA (mRNA) using polymerase
chain reaction (PCR) was devised in 1992 [7] and 
DIFFERENTIAL EXPRESSION OF NUDT9 AT
DIFFERENT PHASES OF THE MENSTRUAL CYCLE AND
IN DIFFERENT COMPONENTS OF NORMAL AND
NEOPLASTIC HUMAN ENDOMETRIUM
Ling-Yun Chen1, Tze-Ho Chen2†, Pao-Ying Wen1,3, Chia-Hung Chou4, Tsung-Ho Ying1,5, 
Shun-Ping Chang6, Gwo-Chin Ma1,3,6, Ming Chen2,3,6,7,8*
1Institute of Biochemistry and Biotechnology, School of Medicine, Chung-Shan Medical University, Taichung, 
Departments of 2Obstetrics and Gynecology, and 3Genomic Medicine, Changhua Christian Hospital, Changhua, 
4Department of Oncology, National Taiwan University, College of Medicine, and Hospital, Taipei, 5Department of 
Obstetrics and Gynecology, Chung-Shan Medical University Hospital, Taichung, 6Department of Medical Research, 
Changhua Christian Hospital, Changhua, and Departments of 7Obstetrics and Gynecology, and 8Medical Genetics 
National Taiwan University, College of Medicine and Hospital, Taipei, Taiwan.
SUMMARY
Objective: The human endometrium manifests different and distinct morphologies and physiologies during the
different phases of the menstrual cycle. We aimed to determine which candidate genes demonstrate differential
expression patterns in the endometrium during different phases of the menstrual cycle.
Materials and Methods: Using differential display reverse transcription polymerase chain reaction to compare
day 5 and day 18 human glandular endometrium obtained by laser capture microdissection, we identified 
a specific gene, NUDT9 (nucleoside diphosphate-linked moiety X motif 9). NUDT9 is known to function as a
highly specific adenosine diphosphate ribose pyrophosphatase and has been mapped to chromosome 4q22.1.
It gives rise to two alternatively spliced messenger RNAs, NUDT9α and NUDT9β, encoding a member of the
Nudix hydrolase family. In this study, we purified NUDT9 protein and produced an antibody, which we then
used for immunohistochemical studies.
Results: Using this anti-NUDT9 antibody, we successfully demonstrated that NUDT9 protein was differentially
expressed in endometrial glandular cells at different phases of the menstrual cycle. NUDT9 was also found to be
expressed more prominently in the epithelial glandular component than in the stromal component of human
endometrial carcinomas.
Conclusion: We suggest that NUDT9 may be involved in the regulation of the menstrual cycle and may be related
to the proliferation of glandular cells in the human endometrium. [Taiwan J Obstet Gynecol 2009;48(2):96–107]
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was used, combined with laser capture microdissection
(LCM), by Torres et al in 2002 to study the endome-
trium of rhesus monkeys, and in human invasive endo-
metrial carcinoma [1,8]. Our laboratory implemented
a research project to identify genes that are differen-
tially expressed in the proliferative endometrium, com-
pared with the secretory endometrium. Various gene
sequences were obtained, including NUDT9 (nucleoside
diphosphate-linked moiety X motif 9), which codes for
an enzyme with pyrophosphatase activity using adeno-
sine diphosphate ribose (ADPR) as its substrate [9–11].
It is an ADPR phosphatase that hydrolyzes ADPR to
adenosine monophosphate and ribose-5-phosphate.
The NUDT9 gene has two transcripts, NUDT9α (the
dominant form, which contains the N-terminus leader
sequence to the mitochondria) and NUDT9β (the aber-
rantly spliced form). The protein belongs to a super-
family of Nudix hydroxylases that catabolize potentially
toxic compound within the cells [12]. It shares 39%
sequence homology with the C-terminus cytoplasmic
domain of the ADPR-gated calcium channel TRPM2
(transient receptor potassium channel 2) and is involved
in the regulation of TRPM2 [13,14]. NUDT9 protein is
expressed in the heart, skeletal muscles, liver, kidneys,
and pancreas. However, its functions and expression
are not yet fully understood [15]. In this study, we used
immunohistochemistry to evaluate the expression pro-
files of NUDT9 in the endometrium during the prolifera-
tive and secretory phases, and in endometrial carcinoma.
Materials and Methods
Sample collection
Endometrial tissue fragments were obtained from sur-
gical specimens of uteri removed because of benign
uterine myoma. The patients, aged 30–50 years old
(median, 42 years), had regular menstrual cycles with-
out menometrorrhagia (indications for hysterectomy
were pain or cancer risk). All patients had given birth
to at least one child. In addition, for all patients, the
pathology of the endometrium revealed no atypia,
polyps, or cancer. Day 5 (proliferative phase, confirmed
by pathologists) endometrium from six patients and
day 18 (secretory phase, confirmed by pathologists)
endometrium from four matched, controlled patients
were obtained and stored at −80°C in Tissue-Tek OCT
(Sakura Finetek Inc., Torrance, CA, USA) embedding
compound prior to further processing. Paraffin sections
of endometrioid-type endometrial carcinoma (n = 12),
proliferative-phase endometrium (n=16), and secretory-
phase endometrium (n = 14) were also retrieved from
the tissue bank for study.
LCM and total mRNA extraction
Cryostat sections were cut at −20°C at a thickness of
3–5 μm, placed on untreated plain glass slides, and
immediately fixed in 75% ethanol prior to LCM. Slides
were stained with hematoxylin and eosin using the 
following sequential solutions (10–30 seconds each):
hematoxylin, distilled water, bluing reagent, 70% etha-
nol, 95% ethanol, and eosin Y. All solutions, including
the stains, were supplemented with 0.5 U/μL of ribo-
nuclease inhibitor (Promega, Madison, WI, USA). Slides
were then dehydrated with two washings in 95% etha-
nol (10 seconds each) and two washings in 100% etha-
nol (10 seconds each). They were then washed twice in
xylene (5 minutes each) and dried in a vacuum desicca-
tor for 20 minutes prior to LCM. Glandular epithelial
cells were harvested using a PixCell II LCM system
(Arcturus Engineering, Mountain View, CA, USA),
according to a protocol modified from Torres et al [1].
Tissue was collected on CapSure TF-100 caps (Arcturus
Engineering) containing transfer film from two or three
sections for each sample. Tissue samples from the
same phase were pooled for subsequent analysis. RNA
was extracted using a PicoPure RNA isolation kit and
ExtracSure assembly in an alignment tray (Arcturus
Engineering), following the manufacturer’s recommen-
dations. Briefly, the cap containing laser-captured cells
was aligned in the ExtracSure assembly and filled with
10 μL of extraction buffer. After centrifugation to col-
lect cell extract in a microcentrifuge tube, 10 μL of 70%
ethanol was added to the cell extract and loaded onto
a preconditioned RNA purification column. The cell
extracts were then purified on the RNA purification
column. The RNA was eluted in 11 μL of nuclease-free
water and stored at −80°C [16].
Differential display reverse transcription PCR
(DDRT-PCR)
Three micrograms of RNA and 3 μL H-T11A primer
(2 μM) were mixed and the total volume was made up
to 19.85 μL by adding diethyl pyrocarbonate-treated
water. The solution was heated at 70°C for 10 min-
utes and then bathed in ice for 1 minute, followed by
mixing with 6 μL of 5X buffer, 3.4 μL of 250 μM dNTP,
and 0.75 μL of Maloney murine leukemia virus reverse
transcriptase (200 U/μL) to give a total volume of 30μL.
The solution was incubated at 37°C for 60 minutes,
then at 75°C for 5 minutes (to inactivate the reverse
transcriptase). One microliter of complementary DNA
(cDNA; produced by the above steps) was then used
for PCR reaction with the following reagents: 25 μM
dNTP, H-T11A primer (2μM), random primers (HAP13–
HAP24, 1 μL each, 2 μM; GenHunter Co., Nashville,
TN, USA), 1 μL of 10X buffer, 0.1 μL of 1.25 U DNA
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polymerase (Takara Bio Inc., Japan), 0.1 μL of α-
35S-deoxyadenosine triphosphate (temperature needed
to be restored in oven before use), and 5 μL of water
(to ensure PCR quality). The conditions for PCR were:
95°C for 5 minutes, then 40 cycles at 95°C for 30 sec-
onds, 40°C for 2 minutes, 72°C for 30 seconds, then
72°C for 7 minutes. Gel electrophoresis was per-
formed using 6% polyacrylamide DNA sequencing
gels. The results were analyzed with PhosphorImager
(Amersham Biosciences, Uppsala, Sweden). Reverse tran-
scription PCR products that were differentially expressed
in day 5 and day 18 endometrium were recovered, re-
amplified with PCR, inserted into pGEM-T Easy Vector
(Promega) and sent for sequencing, according to
methods modified from Bauer et al [17].
Sequence comparisons
Sequences obtained from DDRT-PCR were matched
with known sequences in the GenBank (National Center
for Biotechnology Information, USA) databases to
determine if they were already known or were novel
sequences.
Total mRNA extraction and preparation of 
NUDT9 cDNA by reverse transcription PCR
Tissues in RNA lysis buffer (Micro-to-Midi Total RNA
Purification System, Invitrogen, Carlsbad, CA, USA)
were disrupted using Kontes pestles (Fisher Scientific,
Pittsburgh, PA, USA). Total mRNA was extracted, fol-
lowing the manufacturer’s instructions: tissue lysate
was centrifuged (15,000g, 3 minutes) and the cleared
lysate was mixed with 700 μL of 70% ethanol. The
reaction mixture was washed over an RNeasy mini col-
umn (Qiagen, Hilden, Germany), eluted using 50 μL 
of nuclease-free water, and stored at −80°C. Three
micrograms of RNA and 3 μL of H-T11A primer (2 μM)
were mixed and the total volume was made up to
19.85μL by adding diethyl pyrocarbonate-treated water.
The solution was heated to 70°C for 10 minutes and
then bathed in ice for 1 minute, followed by mixing
with 6 μL of 5X buffer, 3.4 μL of 250 μM dNTP, and
0.75 μL of Maloney murine leukemia virus reverse tran-
scriptase (200 U/μL) to give a total volume of 30 μL.
The solution was incubated at 37°C for 60 minutes,
then at 75°C for 5 minutes (to inactivate the reverse
transcriptase). Five microliters of cDNA (produced by
the above steps) was added with 2 μL of forward primer
with a BamHI site (5-CAC TTG GGA TCC TCT GGT
TCT AAT GGT TCC-3), 2 μL reverse primer with a
HindIII site (5-CAC TTG AAG CTT TCC ACT GCT ATC
CCT TTT-3), 2 μL dNTP (25 μM), 0.5 μL DNA poly-
merase (TaKaRa, 1.25 U), 6.5 μL water (for PCR qual-
ity), and 2 μL 10X buffer. PCR conditions were 95°C
for 5 minutes, then 35 cycles at 95°C for 45 seconds,
50°C for 45 seconds, 72°C for 1 minute, then 72°C for
10 minutes. A gene product anticipated to be NUDT9
was recovered and PCR was repeated. The final product
was analyzed in an ethidium bromide-containing 1%
agarose gel and purified using a Viogene gel extraction
kit, following the manufacturer’s instructions.
Ligation
An insert sequence of NUDT9 was recovered from the
1% agarose gel embedded with the PCR product from
the previous section treated with BamHI and HindIII,
using a QIAquick gel extraction kit (Qiagen). pET32a
plasmids were also treated with BamHI and HindIII
and acted as the vector DNA. The insert DNA was
mixed with the vector DNA at a ratio of 3:1 and then
admixed with T4 DNA ligase, 10X buffer, and double
distilled water at 16°C for 16 hours, as instructed by
the manufacturer (Promega).
Preparation of competent cells
Escherichia coli JM109 cells are endonuclease-deficient
(endA−) and recombination-deficient (recA−), and were
selected for our experiments. Two microliters of JM109
cell cultures were incubated overnight and transferred
to 50-mL cultures for further incubation at 37°C, until
the absorbance at 600 nm was 0.6–0.8. The E. coli cul-
tures were centrifuged at 3,000 rpm (Beckman rotor
JA-14; Beckman Coulter, Fullerton, CA, USA) for 15 min-
utes, and the supernatant was removed using aseptic
techniques. The pellet was mixed in ice with 45 mL 
of sterile titration buffer (100 mM CaCl2 buffer) for 
60 minutes. Further centrifugation was performed at
3,000 rpm for 15 minutes. The supernatant was again
removed. The pellet was admixed with 1 mL of titration
buffer. Glycerol was added to a final concentration of
40%. Pellets were stored at −80°C.
Transformation
Ten microliters of the pET32a/NUDT9 ligation prod-
uct was well mixed into 50 μL of competent cells and
placed on ice for 30 minutes, followed by heat shock
in a water bath at 42°C for 2 minutes 45 seconds, fol-
lowed by immediate placing on ice for 5 minutes. The
cells were cultured in 800 μL of Luria-Bertani medium
for 2 hours. Two hundred-microliter cultures were inoc-
ulated on plates containing ampicillin (100 μg/mL) for
further culture at 37°C for 16–18 hours. Positive clones
were subsequently screened.
Preparation of NUDT9 protein extracts
Three milliliters of E. coli strain BL21 (DE3) cells con-
taining pET32a/NUDT9 were inoculated at 1:100 into
400 mL of LB medium containing ampicillin (100 mg/
mL). When the absorbance at 600 nm reached 0.8–1.0,
isopropyl-β-D-thiogalactopyranoside (IPTG) was added
to the remaining cultures to 1 mmol/L of final concen-
tration, and expression induction (250 rpm, 37°C)
was continued for a further 4 hours. The cultures were
centrifuged at 10,000 rpm (Beckman rotors JA-14 and
JA-17) for 10 minutes each. Cultures were suspended
in lysis buffer (20 mM Tris-HCl, 1 mM phenylmethane-
sulphonylfluoride, 0.3 mM NaCl, 10 mM imidazole) and
then processed using an SLM Aminco French pressure
cell press (Model FA-030; SLM Aminco, Urbana, IL,
USA) 6–8 times. The broken cells were then centrifuged
at 10,000 rpm (Beckman rotor JA-17) for 10 minutes.
The supernatant was further centrifuged at 56,000 rpm
(Beckman rotor Ti90) for 1 hour. The pellets were dis-
carded and the supernatant recovered. NUDT9 fusion
protein was now available for further analysis.
Purification of fusion protein by nickel-nitrilotriacetic
acid (Ni-NTA) affinity chromatography
Ni-NTA resin was pre-balanced with buffer (20 mM
Tris-HCl, 200 mM NaCl, 10 mM imidazole). Four hun-
dred milliliters of protein extracts was mixed with 1 mL
of Ni-NTA resin (Qiagen) and purified through the 
Ni-NTA column (10 cm long and 1 cm in diameter) using
wash buffer (20 mM Tris-HCl, 300 mM NaCl, 25 mM
imidazole) and elution buffer (20 mM Tris-HCl, 300 mM
NaCl, 500 mM imidazole), according to the manufac-
turer’s instructions. Every 1 mL of eluted fluid was col-
lected in a tube and a total of 9 mL was obtained. Tubes
were marked as E1–E9. The resulting samples were ana-
lyzed by sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and Coomassie blue staining.
Quantification of NUDT9 protein
Concentration of NUDT9 protein extracts was deter-
mined after standardization with bovine serum albu-
min (BSA; Sigma-Aldrich, St Louis, MO, USA) stained
with Bradford dye. Briefly, 0, 4, 8, 12, 16, 20 or 24 μL
of BSA (0.5 mg/mL) was added to 800 μL of ddH2O.
The absorbance at 595 nm was determined and a stan-
dard curve for BSA was generated. The concentrations
of the NUDT9 protein extracts were then determined
according to the BSA curve.
Preparation of rabbit anti-NUDT9 polyclonal
antibody
Purified NUDT9 protein was used as antigen at a concen-
tration of 1 mg/mL and mixed with Freund’s complete
adjuvant (Sigma-Aldrich) at a ratio of 1:1 (v/v), follow-
ing the manufacturer’s instructions. Then, 300–500 μL
was injected subcutaneously into rabbits at four sites.
The booster antigen was made by mixing purified NUDT9
fusion protein (0.5 mg/mL) with Freund’s incomplete
adjuvant (Sigma-Aldrich) at a ratio of 1:1 (v/v). Booster
injections were given every other week using the same
dosage and same method of administration as the 
initial injection.
Western blotting
Western blotting of cloned pET32a/NUDT9 was per-
formed according to the local standard protocol in our
laboratory, using 10% SDS-PAGE, with polyvinylidene-
fluoride as the transfer membrane. Rabbit anti-NUDT9
antibody was used as the first antibody, with horseradish
peroxidase-conjugated anti-rabbit IgG as the secondary
antibody (modified from Burnette et al [18] and follow-
ing the instructions of the manufacturers, PerkinElmer
and Sigma-Aldrich). The SuperSignal West Pico chemi-
luminescent substrate kit (Thermo Fisher Scientific
Inc., Waltham, MA, USA) was used, and detection
was performed using a LAS-1000 luminescent image
analyzer (Fujifilm, Tokyo, Japan). In addition, NUDT9
protein expression in various cell lines, including A549
(lung carcinoma cell), CH27 (human lung squamous
carcinoma cell), H460 (human lung non-small cell
carcinoma cell), Hep3B (human hepatoma cell line),
Huh7 (human hepatoma cell line), HUVEC (human
umbilical vein endothelial cells), OK (renal epithelial cell
line), RK3E (rat kidney epithelial cells), THP1 (human
monocytic cell line) and RVSMC (rat vascular smooth
muscle cell), was also analyzed by Western blotting,
using similar procedures and protocols to those listed
above.
Immunohistochemical staining of NUDT9 in
proliferative-phase endometrium, secretory-phase
endometrium, and endometrial carcinoma
Immunostaining was performed using the streptavidin-
biotin-peroxidase method [19,20]. Briefly, 5–6-μm thick
sections were cut from each paraffin block and placed
onto slides. The specimens were then deparaffinized in
xylene and rehydrated in graded alcohols and distilled
water. The endogenous peroxidase was consumed by
immersing the sections in 3% hydrogen peroxide in
absolute methanol for 20 minutes. Pressurized steam
heat was applied to the slides while in a 10 mM citrate
buffer solution (containing 0.1% nonylphenoxypoly-
ethoxyethanol), pH 6.0, for 30 minutes. Nonspecific
secondary antibody binding was blocked by incuba-
tion in 5% normal goat serum for 30 minutes. Affinity-
purified rabbit anti-NUDT9 antibody, at a dilution of
1:100, was then applied for 90 minutes. The primary
antibody was washed off with phosphate-buffered saline
(PBS). The slides were then incubated with biotinylated
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goat anti-rabbit IgG antibody (1:30), followed by
streptavidin-peroxidase (1:30) for 20 minutes each.
The chromogen 3,3-diaminobenzidine tetrahydrochlo-
ride was then applied and reacted with the sections for
10 minutes. After washing in PBS, the sections were
lightly counterstained with hematoxylin, washed in
xylene, and coverslips were applied.
Immunofluorescence by confocal microscopy
Rabbit anti-NUDT9 antibody was mixed with pET32a
to inhibit nonspecific binding prior to the experiment.
The rabbit anti-NUDT9 antibody was then titrated to
a titer of 1:100 and was incubated with the slides
coated with A549 (lung carcinoma cell line), Huh7
(human hepatoma cell line) or HUVEC (human umbil-
ical vein endothelial cells) cells. The three cell lines were
provided by one of the coauthors (L.Y.C.). The slides were
prepared at 37°C for 60 minutes, then washed with 1X
PBS for 10 minutes at least three times. Titrated fluo-
rescein isothiocyanate-conjugated secondary antibody
at a titer of 1:200 was then incubated with the slides at
37°C for 30 minutes in darkness. The slides were washed
with 1X PBS for 10 minutes, at least three times. The
slides were mounted in a mixture of PBS and glycerol
(1:1, v/v) and were observed under a laser confocal
microscope (Leica Microsystems, Wetzlar, Germany).
Statistical analysis
Statistical analyses were performed using SPSS 12.0
(SPSS Inc., Chicago, IL, USA). Nonparametric tests were
chosen because of the small sample size and an inability
to assume that the data followed a normal distribution.
Fisher’s exact test was used to compare the intensity of
staining between secretory-phase endometrium and
proliferative-phase endometrium. The Mann-Whitney
test was used to compare the degree of staining of
epithelial cells in endometrial cancers with that of the
stromal cells in endometrial cancers. A p value < 0.05
was considered to be statistically significant.
Results
Sequences found by DDRT-PCR
DDRT-PCR revealed 26 sequences that showed marked
differences in expression between day 5 and day 18
endometrium. Twelve out of the 26 sequences were
later found to be the results of contamination by mito-
chondrial DNA. We were unable to find matches in
the GenBank database for five of the 26 sequences,
and three of the 26 sequences were reported cDNA
sequences with unknown functions. The remaining 
six sequences were matched to well-documented gene
sequences (Table 1). We concentrated on one of these
six sequences that was much more strongly expressed
in day 5 endometrium than in day 18 endometrium
(Figure 1). The sequence of the PCR product was
22
18 5
∗
Figure 1. Levels of expression of NUDT9 in day 5 and day 18
endometrium were found to be markedly different, using 
differential display reverse transcription polymerase chain
reaction (PCR). PCR of complementary DNA generated by
reverse transcription of total messenger RNA extracted from
day 5 (lane 5) and day 18 (lane 18) endometrium revealed 
a much higher expression of this PCR product in day 5
endometrium (*) than in day 18 endometrium.
Table 1. Genes with differential expression profiles in the human endometrium at different phases of the menstrual cycle 
(day 5–18)
Gene locus Protein
Chromosome Size of sequences Homology with human
locus obtained (bp) loci (%)
SPG4 Spastin 2p21–22 798 (sequence 1) 98 (sequence 1)
846 (sequence 2) 98 (sequence 2)
NUDT10 NUDT10 Xp11.23 643 98
TMOD3 Tropomodulin 3 15q21.1–21.2 1,393 99
PLSCR4 Phospholipid scramblase 4 3q24 505 93
NUDT9 NUDT9 4q22.1 664 96
determined to be: 5-TGCATCCAACGCGTTGGGAG-
CTCTCCCATATGGTCGACCTGCAGGCGGCCGCGAA-
TTCACTAGTGATTAAGCTTACCAGGTGAGATAATGG-
ATAATCTTATGCTAGAAGCTGGAGATGATGCTGGAA-
AAGTGAAATGGGTGGACATCAATGATAAACTGAAG-
CTTTATGCCAGTCACTCTCAATTCATCAAACTTGTG-
GCTGAGAAACGAGATGCACACTGGAGCGAGGACT-
CTGAAGCTGACTGCCATGCGTTGTAGCTGATGGTC-
TCCGTGTAAGCCAAAGGCCCACAGAGGAGCATACT-
GAAAAGAAGGCAGTATCACAGAATTTATACTATA-
AAAAGGGCAGGGTAGGCCACTTGGCCTATTTACTT-
TCAAAACAATTTGCATTTAGAGTGNTTCGCATCAGA-
ATAACATGAGTAAGATGAACTGGAACACAAAAT-
TTTCAGCTCTTTGGTCAAAAGGAATTTAAGTAAT-
CATATTTTGGATGGATTCGAATTAAGCATGGCTTAA-
AATAATTTAAACCACTATGCTCTTTGAGATCATTA-
TCAGATAAAGATAAATCTTGATCAGCTTAAAAAAA-
AAAGCTATCGATTCCGCGCGCATGCGCGACATGCA-
CGTCGGGCCATCGCCTNNGGAGCGATTCCATTACT-
GGCCGCGTTTCACC-3. The sequence was found to
correspond to human NUDT9 by a GenBank search,
with a homology of 96% by Blast2 comparison. The
other five sequences included two from spastin (SPG4),
one from scramblase 4, one from tropomodulin 3,
and one sequence from NUDT10 (Table 1).
Purification of NUDT9 fusion protein
Primers designed for PCR amplification of the endome-
trial tissue extracts needed to avoid the hydrophobic
amino acids and also needed to contain suitable re-
cognition sites for the restriction enzymes BamHI and
HindIII (Figures 2A and 2B). The size of the PCR prod-
uct was 400 bp (Figure 2C). Induction of expression in
E. coli carrying the pET32a/NUDT9 by IPTG revealed a
33-kDa protein (Figure 3) which was compatible with
the size expected (14-kDa NUDT9 plus 19-kDa thio-
redoxin of pET32a). The extracts were then purified 
by Ni-NTA affinity chromatography and blotted by
SDS-PAGE.
Titer in rabbit sera
The titer of the rabbit anti-NUDT9 rose to 1:27,000 at
5 weeks after immunization, but was weaker at 1:81,000
at 7 weeks, and remained at 1:81,000 at 9 weeks after
immunization (Figure 4). Large amounts of anti-sera
were collected at 9 weeks after immunization for future
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51
186
A
B CNUDT9 (NM_024047)
BamHI
GGATCC
CCTAGG
HindIII
AAGCTT
TTCGAA
5' CAC TTG GGA TCC TCT GGT TCT AAT GGT TCC
3' CAC TTG AAG CTT TCC ACT GCT ATC CCT TTT
∼ 400 bp
Figure 2. (A) Amino acid sequence of NUDT9. The hydrophobic amino acids are marked in yellow. The cloned segment of the
NUDT9 peptide included the amino acids between 51 (5-NH2) and 186 (3-COOH). (B) Diagram of the NUDT9 gene and
the design of primers, including a BamHI recognition site (GGATTC) in the 5 end and a HindIII recognition site in the 3 end
(AAGCTT). (C) The polymerase chain reaction product of the segment of the NUDT9 gene being amplified and cloned there-
after. Each lane denotes a sample of endometrium extracts. A 400-bp DNA fragment was noted in each lane, a size compatible
with the predicted size of the cloned segment.
use. To confirm the antigen–antibody relationship, the
anti-sera were used to neutralize the NUDT9 fusion pro-
tein. Western blotting showed disappearance of the
33-kDa signal, indicating that the anti-sera did contain
the specific rabbit polyclonal antibody for the NUDT9
fusion protein (data not shown).
Immunohistochemical study of NUDT9 in human
endometrium
We found a marked increase in the expression of
NUDT9 in the proliferative-phase endometrium com-
pared with the secretory-phase endometrium (Figure 5).
Fourteen out of 16 proliferative-phase endometrial
samples were categorized as ≥ 2+, compared with only
three out of the 14 secretory-phase endometrium sam-
ples (p < 0.001 using Fisher’s exact test if categorized
as a 2 × 2 table; see Tables 2 and 3). The expression of
NUDT9 protein was also much more prominent in
glandular carcinoma cells than in noncancerous stro-
mal cells in human endometrial carcinoma (Figure 6).
Table 4 shows the percentages of positively-stained cells
in both the glandular and stromal samples. Two hun-
dred glandular and 200 stromal cells were counted in
each slide (total of 12 slides and 4,800 cells counted).
A significantly higher percentage of NUDT9-positive
staining was noted in the glandular cells, compared with
the stromal cells (p < 0.05).
Immunofluorescence study of NUDT9 in 
three cell lines
Western blotting of NUDT9 expression in many non-
cancerous and cancerous cell lines revealed that all the
cell lines studied expressed NUDT9 (Figure 7).
Immunofluorescence analysis using a fluorescein
isothiocyanate-conjugated secondary antibody recog-
nizing the rabbit anti-NUDT9 antibody was performed
in A549 (lung carcinoma cell line), Huh7 (human hep-
atoma cell line), and HUVEC (human umbilical vein
endothelial cells) cell lines, with the aid of confocal
microscopy. NUDT9 protein was expressed both in the
nucleus and in the cytoplasm (Figure 8). The nuclear
expression was much more prominent than the cyto-
plasmic expression in HUVEC cells.
Discussion
Human endometrium undergoes cyclic changes marked
by repeated proliferation and breakdown during the
nongestational reproductive period in females. When
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0
1 2 3
hr 5 0 5 0 5
IPTG − + − + − + − + − + − +
47
37
25
19
15
33 kDa
Figure 3. Western blotting of the NUDT9 fusion protein,
showing the results of the three batches of samples (samples
1–3) stained with Coomassie blue to highlight the NUDT9
fusion protein. Addition (+) or non-addition (–) of the in-
ducer, isopropyl-β-D-thiogalactopyranoside (IPTG), at 0 and
5 hours of culture revealed a 33-kDa product in the pET32a
cloning system cultured for 5 hours after IPTG induction.
kD
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A
41
1/1,000 1/3,000 1/81,0001/9,000 1/27,000 1/1,000 1/3,000 1/81,0001/9,000 1/27,000
B
Figure 4. Titers of rabbit anti-sera at different time points. (A) At the first sampling (5 weeks after immunization), the titer
was 1:27,000. (B) At the second sampling (7–9 weeks after immunization), the titer was weaker at 1:81,000.
necessary, it can be transformed into an environment
suitable for implantation and maintenance of pregnancy,
but the mechanisms involved are still not completely
understood. A better understanding of the human
endometrium may lead to breakthroughs in tackling
problems such as implantation failure, early pregnancy
loss, the safety of hormone replacement therapy, and
even tumorigenesis/carcinogenesis. We, therefore, aimed
to identify any genes with differential expression during
the menstrual cycle. Of the potentially available meth-
ods including cDNA microarray, matrix-assisted laser
desorption/ionization time-of-flight mass spectrome-
try and DDRT-PCR, we chose DDRT-PCR because it is
cheaper, easier to perform, and less equipment-
dependent [7,17,21]. LCM was used to ensure that
the cells used for the extraction of mRNA were endo-
metrial glandular cells, rather than a mixture of glan-
dular and stromal cells. This is a critical step when
trying to elucidate trivial differences in gene expression
patterns [16]. No differences in expression of the usual
markers of cell division and proliferation, such as Ki-
67 and proliferative cell nuclear antigen [22,23], were
found between day 5 and day 18 endometrium by
DDRT-PCR in our study. However, we did find several
genes that were differentially expressed in day 5 and
day 18 human endometrium, including the human
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Figure 5. Immunohistochemical staining of proliferative- and secretory-phase endometrium. NUDT9 expression was higher in
the proliferative-phase endometrium than in the secretory-phase endometrium.
Table 2. Distribution of different immunohistochemistry 
(IHC) intensities after staining with anti-NUDT9
IHC category
0 1+ 2+ 3+ Total
Secretory-phase 6 5 3 0 14
endometrium
Proliferative-phase 0 2 8 6 16
endometrium
Table 3. Distribution of different immunohistochemistry 
(IHC) intensities after staining with anti-NUDT9 (further 
categorization)*
IHC category
0 or 1+ 2+ or 3+
Secretory-phase endometrium 11 3
Proliferative-phase endometrium 2 14
*p < 0.001 by Fisher’s exact test.
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NUDT9. The presence of polymorphisms or sequenc-
ing errors hidden in the sequences could account for
the fact that the homology between the sequences
obtained in this study and the reported human gene
sequences were only 93–99%, rather than 100%.
Human NUDT9 maps to chromosome 4q22.1 and
has two alternatively spliced mRNA transcripts: NUDT9α
and NUDT9β. The protein is a member of the Nudix
hydroxylase family (similar to yeast YSA1 and mouse
Nudt5) and is able to hydrolyze ADPR to adenosine
monophosphate and ribose-5-phosphate [11,24]. ADPR
is a product of nicotinamide adenine dinucleotide
hydrolysis and a breakdown product of the calcium-
released second messenger cyclic ADPR [9,14].
The NUDT9α product is a full-length protein with
a mitochondrial leader sequence and is expressed in
the heart, liver, skeletal muscles, kidneys, and pancreas.
The NUDT9β protein, however, lacks the N-terminal
mitochondrial sequence and an intron, when com-
pared with the NUDT9α protein [15]. Free ADPR is
regarded as a toxic substance within the cell, but may
be involved in the regulation of TRPM2, a transient
calcium-permeable cation channel. TRPM2 is gated by
oxidative and nitrosative stress. Its NUDT9 homology
domain is critical for its activation by ADPR [12]. A
previous study revealed that splicing variants of TRPM2,
lacking some 34-amino acid residues, were insensitive
to ADPR. Besides, if nicotinamide adenine dinucleotide
hydrolysis was inhibited, or specific enzymes cleaved
ADPR, the gating of TRPM2 was also suppressed. Such
findings indicate an intimate relationship between
NUDT9 and TRPM2 [13,14].
Table 4. Distribution of NUDT9-positive cells and their relative abundances in the glandular and stromal compartments 
of human endometrial carcinoma specimens
Distribution of NUDT9-positive cells (%)
Relative abundance
0 1–5 6–25 26–50 51–75 76–100 Total
Glandular 0 0 0 1 3 8 12
Stromal 1 4 7 0 0 0 12
50×
200×
100×
400×
Figure 6. Immunohistochemical staining of sections of human endometrial carcinoma revealed higher NUDT9 expression 
in the glandular cells than in the stromal cells. Strong staining of NUDT9 protein was noted in the nuclei of the tumor cells.
NUDT9α is an evolutionarily conserved mitochon-
drial ADPR pyrophosphatase and is thus specific to mito-
chondria and functions as a monomer [10]. It has been
speculated that NUDT9 might regulate the intracellular
concentration of ADPR and help energy production.
NUDT9 has also been used as a marker for mitochondria
[24]. However, there have been only a few studies of
NUDT9 and its functional relevance [13,14,24].
We used the amino acid sequence from 51–186 of
the NUDT9 protein (Figure 2A). This segment shows
100% sequence identity between the two alternatively
spliced mRNAs of NUDT9. Our anti-NUDT9 antibody
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Figure 8. Immunofluorescence analysis of NUDT9 in three cell lines (A549, Huh7, HUVEC). β-Actin was used as a control;
the images of NUDT9 and β-actin staining are merged. Marked nuclear expression of NUDT9 was demonstrated in the
HUVEC cells. All three cell lines showed positive staining for NUDT9 in both the nucleus and in the cytoplasm.
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Figure 7. Expression of NUDT9 by Western blotting in 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis for 
the cell lines: A549 (lung carcinoma cell), CH27 (human lung squamous carcinoma cell), H460 (human lung non-small cell
carcinoma cell), Hep3B (human hepatoma cell line), Huh7 (human hepatoma cell line), HUVEC (human umbilical vein
endothelial cells), OK (renal epithelial cell line), RK3E (rat kidney epithelial cells), THP1 (human monocytic cell line), and
RVSMC (rat vascular smooth muscle cells).
should, therefore, be able to recognize both NUDT9α
and NUDT9β. NUDT9 can degrade the toxic substance
ADPR in cells; thus, it is possible that an increased
level of NUDT9 expression may prevent apoptosis or
cell death, thus contributing to cell proliferation and
even carcinogenesis. This could partly explain why 
the proliferative-phase endometrium expressed more
NUDT9 than the secretory-phase endometrium, and
also why glandular cancer cells had a higher level of
NUDT9 expression than the adjacent stromal, non-
cancerous cells. NUDT9α, the major form of NUDT9
transcript, is thought to be localized within or associ-
ated with mitochondria, which are in turn considered
to be involved in coordinating cell death or apoptosis.
Increased NUDT9 expression could thus be a by-product
of increased numbers of mitochondria in cancer cells
or cells with a high proliferative index. Alternatively,
NUDT9 could itself contribute to cell proliferation and
carcinogenesis, independent of its association with mito-
chondria. Further studies are needed to clarify this
relationship, as well as its relationship with proteins
and enzymes involved in cell cycle regulation, such as
cyclin D1, cyclin E, p53, p21, and hormones such as
estrogen, progesterone and their receptors. Notably,
all the cell lines studied in this report, whether cancer-
ous or noncancerous in origin, had detectable (if vari-
able) levels of NUDT9 expression (Figure 7). Nuclear
expression of NUDT9 was noted in A549, Huh7 and
HUVEC cells (Figure 8), implying that its distribution
was not restricted to the mitochondria. The alterna-
tively spliced NUDT9β, or other products of NUDT9
degradation, may account for the nuclear expression
noted in our study. Because NUDT9 is expressed in
many cell lines, in both the nucleus as well as the cyto-
plasm, its detection in other gynecologic cancers (as
for the Haymaker p38.5 protein in the carcinogenesis
of gynecologic cancers), or even in cancers of other
origins, may help to clarify its real role in carcinogene-
sis [20,25]. Previous studies of NUDT9 have mostly
focused on its biochemical functions and structural
relevance. Our study thus appears to be the first to
identify NUDT9 as a potential biomarker for human
endometrium and endometrial carcinogenesis.
In summary, we identified NUDT9 as a gene that is
differentially expressed during different phases of men-
struation in the human endometrium. This was con-
firmed by immunohistochemistry that showed NUDT9
to be more highly expressed in proliferative-phase endo-
metrium than in the more quiescent, secretory-phase
endometrium. We also revealed that NUDT9 is widely
expressed at the protein level in actively proliferating
cells, and is expressed in both the nucleus and cytoplasm.
Finally, we demonstrated that glandular epithelial cells
expressed more NUDT9 than stromal cells in human
endometrial carcinomas. Thus, NUDT9 is involved in and
can be a biomarker of proliferation of human glandular
endometrial cells. Based on these findings, we suggest
that this molecule could be associated with tumorige-
nesis in the human endometrium.
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